CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 309 enrolled
Drug / intervention
MenABCWY +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04440176
NCT04440176Phase 2Completed
CompareCT.gov

A PHASE 2b, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MenABCWY ADMINISTERED ON 2 DIFFERENT DOSING SCHEDULES IN HEALTHY PARTICIPANTS ≥11 TO <15 YEARS OF AGE

Pfizer·interventional·Posted Jun 19, 2020·Updated Apr 27, 2026

In Brief

A Phase 2 clinical trial evaluating MenABCWY and Saline for Meningococcal Vaccine. Completed, enrolled 309 participants across 20 sites.

Detailed Summary

This study is designed to describe the short-term immunogenicity and safety of 2 doses of Neisseria meningitidis group A, B, C, W, and Y vaccine (MenABCWY) separated by either 12 or 36 months during adolescence, and immunopersistence up to 24 months after completing 2 doses separated by a 12-month interval.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMeningococcal Vaccine
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedJun 19, 2020
Enrollment StartJun 17, 2020
Primary CompletionJan 5, 2024
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 6.0 years ago

Interventions

MenABCWYbiological

Neisseria meningitidis group A, B, C, W, and Y vaccine

Salinebiological

Placebo